Please select the eligibility criteria that correspond to the clinical trial below.
Title: CPIC is a Community Partnered Participatory Research (CPPR) Project of Community and Academic Partners Working Together to Learn the Best Way to Reduce Depression in Our Communities.
Brief Summary: CPIC is a community initiative and research study funded by the NIH. CPIC was developed and is being run by community and academic partners in Los Angeles underserved communities of color. CPIC compares two ways of supporting diverse health and social programs in under-resourced communities to improve their services to depressed clients. One approach is time-limited expert technical assistance coupled with culturally-competent community outreach to individual programs, on how to use quality improvement toolkits for depression that have already been proven to be effective or helpful in primary care settings, but adapted for this study for use in diverse community-based programs in underserved communities. The other approach brings different types of agencies and members in a community together in a 4 to 6-month planning process, to fit the same depression quality improvement programs to the needs and strengths of the community and to develop a network of programs serving the community to support clients with depression together. The study is designed to determine the added value of community engagement and planning over and above what might be offered through a community-oriented, disease management company. Both intervention models are based on the same quality improvement toolkits that support team leadership, care management, Cognitive Behavioral Therapy, medication management, and patient education and activation. Investigators hypothesized that the community engagement approach would increase agency and clinician participation in evidence-based trainings and improve client mental health-related quality of life. In addition, during the design phase, community participants prioritized adding as outcomes indicators of social determinants of mental health, including physical functioning, risk factors for homelessness and employment. Investigators hypothesized by activating community agencies that can address health and social services needs to engage depressed clients, these outcomes would also be improved more in the collaboration condition. Investigators also hypothesized that the collaboration approach would increase use of services.


Options:
A: Inclusion Criteria:

Administrators

* Age 18 and above
* Work or volunteer for an enrolled program in the study and be designated as a liaison by the program

Providers

* Age 18 and above
* Have direct contact with patients/clients

Clients

* Age 18 and above
* Score 10 or greater on modified Patient Health Questionnaire (PHQ-8)

Exclusion Criteria: grossly disorganized by screener staff assessment Not providing personal contact information

Administrators - Under age 18

Providers

- Under age 18

Clients

* Under age 18
* Gross cognitive disorganization by screener staff assessment
* Providing no contact information
B: Inclusion Criteria:

1. HIV-infected women (and their infants) who present to ANC or delivery with unknown HIV status;
2. HIV-infected women (and their infants) with previous history of ARV prophylaxis or treatment, but who are not on prophylaxis or treatment at the time of presentation for antenatal care or delivery.

Exclusion Criteria:

HIV-infected women with known status who are on ARV prophylaxis or treatment at the time of presentation to ANC.
C: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* A male or female child of:5-17 months (inclusive) of age at time of first vaccination,or between 6-12 weeks of age at time of first vaccination and NOT have already received a dose of vaccine against diphtheria, tetanus or pertussis or Hemophilus influenzae type B and must be \> 28 days of age at screening.
* Signed informed consent or thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child.
* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.

All subjects must satisfy the following criteria at the start of the extension phase:

* Subjects who were enrolled and who received at least one vaccine dose in the primary trial phase.
* Subjects who were present for Visit 35 on or before 30 September 2013.
* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. return for follow-up visits) should be enrolled in the study.

Exclusion Criteria:

The following criteria should be checked at the time of study entry. If any apply, the subject must not be included in the study:

* Acute disease at the time of enrollment.
* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality.
* Anemia associated with clinical signs or symptoms of decompensation or hemoglobin ≥ 5.0 g/dL.
* Major congenital defects.
* History of allergic reactions, significant IgE-mediated events or anaphylaxis to previous immunizations.
* Children with a past history of a neurological disorder or atypical febrile seizure.
* Children with malnutrition requiring hospital admission.
* Children currently meeting the criteria for HIV disease of Stage III or Stage IV severity as defined by the World Health Organization.
* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to a drug or vaccine that is not licensed for that indication with the exception of studies with the objective of improving the drug treatment or clinical management of severe malaria disease.
* Use of a drug or vaccine that is not approved for that indication other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
* Previous participation in any other malaria vaccine trial.
* Receipt of a vaccine within the preceding 7 days.
* Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.
* Any other findings that the investigator feels would result in data collected being incomplete or of poor quality
D: Inclusion Criteria:

* Age 18 years or older
* Have a home address and telephone number
* Willing to participate in all study components
* Willing to be followed for 6 months
* Smoked at least 100 cigarettes in their lifetime
* Current smoker
* American Indian or Alaska Native

Exclusion Criteria:

* Planning to leave the state within next 24 months
* Pregnant or breast feeding or planning to become pregnant in next 4 months.
* Medically ineligible after screening

Answer: A